Daiichi Sankyo Singapore is launched to expand the reach of its antibody-drug conjugates for people living with cancer

Daiichi Sankyo Singapore Pte. Ltd. (hereafter, Daiichi Sankyo Singapore), a subsidiary of Daiichi Sankyo Company, Limited (TSE: 4568), has been launched.

Daiichi Sankyo Singapore will be dedicated to bridging unmet needs in oncology, in hopes of extending and improving the lives of cancer patients, with cancer accounting for almost 30% of all deaths in Singapore. Daiichi Sankyo Singapore will focus on antibody-drug conjugates (ADCs), a class of drugs that offer targeted precision and potent drug delivery to certain tumour types, by delivering potent cancer-killing agents directly to cancer cells to eliminate them, whilst limiting damage to healthy surrounding cells.

“We are committed to creating new employment and treatment opportunities in Singapore, and look forward to close partnership with the relevant professional and patient communities to bring forward new methods of drug delivery.”

As part of the Daiichi Sankyo Quality Assurance organisation, the newly set up RDPV QA (Research & Development, Pharmacovigilance, and Quality Assurance) function in Singapore signifies a strategic leap forward in reinforcing our commitment to patients, customers, and rigorous quality assurance in all that we do. This Asia Pacific regional hub will be a centre of excellence, driving the mission of 'Patient first, Quality Always' while ensuring the highest Quality standards in Research & Development, Pharmacovigilance, Medical Affairs and key processes and systems across the region.

Daiichi Sankyo’s portfolio currently consists of six DXd ADCs in clinical development across multiple types of cancer, with one of them now in commercialisation.